Wire flash
HealthFDA Advisory Panel Votes to Add Peptides to Compounding List Over Scientist Objections
Editorial responsibility
- No named human review is recorded for this page.
- Source reporting is collected, normalized, translated or condensed automatically when needed.
- Automatically published source-backed update
The FDA's Pharmacy Compounding Advisory Committee (PCAC) voted on Thursday to recommend adding the peptides BPC-157, KPV, TB-500, and MOTS-C to the list of substances that compounding pharmacies are permitted to produce. This decision went against the position of FDA scientists, who raised concerns about the lack of demonstrated clinical benefits and safety data for these peptides. The committee heard public comments and reviewed presentations from agency staff before making its recommendation. The vote marks a significant policy divergence within the FDA regarding the regulation of compounded peptide products.
Source report
The Food and Drug Administration's (FDA) Pharmacy Compounding Advisory Committee (PCAC) voted on Thursday to add certain peptides to the list of substances that compounding pharmacies may produce, diverging from the position of FDA scientists.
The decision came despite concerns raised over the lack of demonstrated benefits for these substances.
Committee Proceedings
The PCAC heard public comments and reviewed presentations by FDA staff members concerning the following peptides:
- BPC-157
- KPV
- TB-500
- MOTS-C
The committee's vote marks a notable break from the agency's scientific staff, who had raised questions about the evidence supporting the use of these peptides.
Source
Just In NewsWestern
Part of this Story
FDA Advisory Panel Votes to Add Peptides to Compounding List Despite Scientist Opposition